A Phase 1, Open-label, Single Dose, Parallel-group Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 20 May 2017
At a glance
- Drugs Palbociclib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 06 Jun 2016 Status changed from recruiting to completed.
- 23 Dec 2014 Planned End Date changed from 1 Jun 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
- 01 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2016 to 1 Jun 2015.